Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.

Hepatology (Baltimore, Md.) - 1 Aug 2007

Buster Erik H C J, Hansen Bettina E, Buti Maria, Delwaide Jean, Niederau Claus, Michielsen Peter P, Flisiak Robert, Zondervan Pieter E, Schalm Solko W, Janssen Harry L A

Abstract excerpt

UNLABELLED: Chronic hepatitis B (CHB) patients with advanced fibrosis are often not considered for treatment with peginterferon (PEG-IFN) because IFN therapy may precipitate immunological flares, potentially inducing hepatic decompensation. We investigated the efficacy and safety of treating hepatitis B e antigen (HBeAg)-positive CHB patients with 52 weeks of PEG-IFN-alpha-2b (100 microg weekly) alone or in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B, Chronic
Share to Hepatitis B e Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B virus

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Liver Cirrhosis

Share to Logistic Models

Share to Polyethylene Glycols

Source

Identifiers

PMID: 17604363
DOI: 10.1002/hep.21723

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.PMID 17604363Read ↗

Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.Semantic proximity Read ↗

Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data.Semantic proximity Read ↗

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.Semantic proximity Read ↗

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.Semantic proximity Read ↗

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.Semantic proximity Read ↗

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Semantic proximity Read ↗

Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT.Semantic proximity Read ↗

Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis.Semantic proximity Read ↗

Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports.Semantic proximity Read ↗

Response and seroconversion rates among HBeAg-positive chronic HBV Egyptian patients treated with peginterferon alpha 2a (Pegasys), a single-centre experience.Semantic proximity Read ↗

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study.Semantic proximity Read ↗

Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.